Torrent Pharmaceuticals Ltd., incorporated in 1972, is a large capitalization company (having a market capitalization of Rs 47840.11 Crore) operating in the pharmaceutical sector.
The main products/revenue segments of Torrent Pharmaceuticals Ltd. include pharmaceuticals, other operating income and export incentives for the year ending March 31, 2021.
For the quarter ended 31-03-2022, the company reported consolidated total revenue of Rs 2187.00 Crore, up 1.44% from last quarter, total revenue of Rs 2156.00 Crore and up up 10.68% from the same quarter last year, total revenue of Rs 1976.00 Crore. The company reported a net profit after tax of Rs -118.00 Crore last quarter.
RECOMMENDEDSTORIES FOR YOU
Torrent Pharma (Torrent) performance at T4FY22 was above estimates for all metrics. Revenue increased 10% year-on-year to Rs 21.3 billion (I-Sec: Rs 20.3 billion) driven by 12.1% growth in India. U.S. sales increased 19.4% quarter-on-quarter to $37 million from an estimated $29 million. EBITDA margin decreased by 370 basis points year-on-year to 26.3% due to a low gross margin. Torrent reported an impairment charge of Rs 4.39 billion for the shutdown of the liquid facility in the United States. Adjusted PAT decreased by 24.2% to 2.5 billion rupees (I-Sec: 2.2 billion rupees). He remains positive on Torrent given his strong national franchise backed by a dominant chronicle segment. Given the share price correction (~14% in the last 6 months), it is moving to BUY from Hold with a revised target price of Rs3,226/share (previously: Rs3,134/share).
The promoters held 71.25% of the company’s capital as of March 31, 2022, while the FIIs held 13.05% and the DIIs 7.56%.
(Disclaimer: The recommendations given in this section or any report attached hereto are written by an external party. The views expressed are those of the respective authors/entities. These do not represent the views of Economic Times (ET). AND does not warrant, for, endorse any of its content and hereby disclaims all warranties, express or implied, relating thereto.Please consult your financial adviser and seek independent advice.